Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.33 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.33 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22216205 | 0.83 | SMN1; SMN2 (0.43) | AKR1C3AKR1C2ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL28425324 | 0.82 | SMN1; SMN2 (0.43) | AKR1C3AKR1C2ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL30329619 | 0.82 | SMN1; SMN2 (0.43) | AKR1C3AKR1C2ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL29441571 | 0.69 | L3MBTL1 (0.39) | AKR1C3AKR1C2ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL22323003 | 0.66 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1MAPTPOLB | |
| SCHEMBL20726604 | 0.65 | GABRA1 (0.48) | AKR1C3AKR1C2ALDH1A1MAPK1KMT2A | |
| SCHEMBL19736052 | 0.63 | ALDH1A1 (0.39) | ALDH1A1TSHRL3MBTL1MAPK1KMT2A | |
| SCHEMBL12497667 | 0.63 | MAPT (0.45) | ALDH1A1TSHRL3MBTL1KMT2AMEN1 | |
| SCHEMBL23918399 | 0.62 | SMN1; SMN2 (0.41) | AKR1C3AKR1C2ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL23918388 | 0.62 | ALDH1A1 (0.53) | AKR1C3AKR1C2ALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371432-B2 | Haloallylamine compounds and application thereof | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-07-29 | — | — | US | disclosed |
| US-20220081439-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | TransThera Sciences (Nanjing), Inc (CN) | 2022-03-17 | — | — | US | disclosed |
| EP-3892621-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371432-B2 | Haloallylamine compounds and application thereof | ADRA1D, ADRA1A, VAPA | GABRA1 246/4885GABRG2 2136/4885GABRB3 1022/4885 |
| US-20220081439-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | ADRA1D, ADRA1A, VAPA | GABRA1 246/4885GABRG2 2136/4885GABRB3 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.